Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.57 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.55 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.55 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11749307 | 0.86 | SLC25A1 (0.68) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL17843843 | 0.85 | DNMT1 (0.56) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL31404884 | 0.85 | SLC25A1 (0.61) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL17843838 | 0.81 | VCAM1 (0.56) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL11752812 | 0.80 | VCAM1 (0.60) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL5956066 | 0.79 | LMNA (0.57) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL1250772 | 0.78 | VCAM1 (0.62) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL15648339 | 0.78 | NHERF1 (0.70) | DNMT1DNMT3AMEN1KMT2AMAPT | |
| SCHEMBL8113261 | 0.78 | MAPT (0.62) | VCAM1DNMT1DNMT3AMEN1KMT2A | |
| SCHEMBL29048726 | 0.77 | FFAR4 (0.77) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107257791-B | Benzimidazole sulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma ROR gamma (t) | 盖尔德马研究及发展公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10618890-B2 | Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-04-14 | — | — | US | disclosed |
| US-20190071433-A1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-03-07 | — | — | US | disclosed |
| EP-3233838-B1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3233838-A1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097393-A1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097393-A1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071433-A1 | BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | VCAM1 3310/4885DNMT1 4458/4885DNMT3A 4040/4885 |
| US-10618890-B2 | Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | VCAM1 3310/4885DNMT1 4458/4885DNMT3A 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.